Survivin, a cancer target with an emerging role in normal adult tissues

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Survivin, an apoptosis inhibitor, is highly expressed in most cancers, correlating with poor prognosis and treatment resistance.
• Emerging evidence shows survivin expression in normal adult cells, including hematopoietic, immune, and endothelial cells, suggesting physiological roles.

Purpose of the Study:

• To review the prognostic significance of survivin in cancer, justifying antisurvivin therapy.
• To differentiate survivin expression and function in normal versus malignant cells.
• To evaluate preclinical antisurvivin therapies considering survivin's roles in normal physiology.

Main Methods:

• Literature review of survivin's prognostic relevance in various cancers.
• Analysis of survivin expression patterns in normal adult tissues.
• Evaluation of preclinical studies on antisurvivin therapies.

Main Results:

• Survivin overexpression is a significant predictor of poor outcomes in many cancers.
• Normal adult cells, particularly those with high turnover, express survivin, implying roles in proliferation and survival.
• Preclinical antisurvivin therapies demonstrate efficacy but require careful consideration of effects on normal tissues.

Conclusions:

• Understanding survivin's dual role in cancer and normal cells is critical for developing safe and effective antisurvivin therapies.
• Targeting survivin in cancer offers a promising strategy, but potential impacts on normal hematopoiesis, angiogenesis, and immune function need thorough investigation.